Produção Nacional
Revisado por pares
Progress on Phage Display Technology: Tailoring Antibodies for Cancer Immunotherapy
2023; Multidisciplinary Digital Publishing Institute; Volume: 15; Issue: 9 Linguagem: Inglês
10.3390/v15091903
ISSN1999-4915
AutoresRenato Kaylan Alves de Oliveira França, Igor Cabral Studart, Marcus Rafael Lobo Bezerra, Larissa Queiroz Pontes, Antonio Marcos Aires Barbosa, Marcelo M. Brígido, Gilvan Pessoa Furtado, Andréa Queiróz Maranhão,
Tópico(s)Advanced Biosensing Techniques and Applications
ResumoThe search for innovative anti-cancer drugs remains a challenge. Over the past three decades, antibodies have emerged as an essential asset in successful cancer therapy. The major obstacle in developing anti-cancer antibodies is the need for non-immunogenic antibodies against human antigens. This unique requirement highlights a disadvantage to using traditional hybridoma technology and thus demands alternative approaches, such as humanizing murine monoclonal antibodies. To overcome these hurdles, human monoclonal antibodies can be obtained directly from Phage Display libraries, a groundbreaking tool for antibody selection. These libraries consist of genetically engineered viruses, or phages, which can exhibit antibody fragments, such as scFv or Fab on their capsid. This innovation allows the in vitro selection of novel molecules directed towards cancer antigens. As foreseen when Phage Display was first described, nowadays, several Phage Display-derived antibodies have entered clinical settings or are undergoing clinical evaluation. This comprehensive review unveils the remarkable progress in this field and the possibilities of using clever strategies for phage selection and tailoring the refinement of antibodies aimed at increasingly specific targets. Moreover, the use of selected antibodies in cutting-edge formats is discussed, such as CAR (chimeric antigen receptor) in CAR T-cell therapy or ADC (antibody drug conjugate), amplifying the spectrum of potential therapeutic avenues.
Referência(s)